Table 3.
Targets with more than one complementary approved therapeutic monoclonal antibody.
| Target | Monoclonal Antibodies |
|---|---|
| Monoclonal antibodies for non-cancer therapy | |
| TNF | Adalimumab; certolizumab pegol; golimumab; infliximab |
| PCSK9 | Alirocumab; evolocumab |
| EBOV GP1 | Ansuvimab-zykl; atoltivimab; maftivimab; odesivimab-ebgn |
| IL-2 receptor α chain (CD25) | Basiliximab; daclizumab |
| VEGF-A | Brolocizumab-dbll; ranibizumab |
| ACE2 RBD of SARS-CoV-2 | Casirivimab + imdevimab; regdanvirimab; Sotrovimab |
| Complement C5 | Eculizumab; ravulizumab-cwvz |
| CGRP | Eptinezumab-jjmr; fremanezumab-vfrm; galcanezumab-gnlm |
| IL-17A | Ixekizumab; secukinumab |
| IL-5 | Mepolizumab; reslizumab |
| α4 integrin | Natalizumab; vedolizumab |
| Bacillus anthracis | Obiltoxaximab; raxibacumab |
| IL-23 p19 | Risankizumab-rzaa; tildrakizumab-asmn |
| IL-6R | Sarilumab; satralizumab-mwge; tocilizumab |
| Monoclonal antibodies for cancer therapy | |
| HER2 | Ado-trastuzumab; fam-trastuzumab; margetuximab-cmkb; pertuzumab; trastuzumab |
| PD-L1 | Atezolizumab; avelumab; durvalumab |
| PD-1 | Cemiplimab-rwlc; dostarlimab-gxly; nivolumab; pembrolizumab |
| EGFR | Amivantamab; Cetuximab; necitumumab; panitumumab |
| CD38 | Daratumumab; isatuximab-irfc |
| GD2 | Dinutuximab; naxitamab-gqgk |
| CD20 | Ibritumomab; obinutuzumab; ofatumumab; rituximab |
| CD22 | Inotuzumab ozogamicin; moxetumomab pasudox-tdfk |